U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Opioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework Guidance for Industry
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Opioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework Guidance for Industry June 2019

Download the Draft Guidance Document Read the Federal Register Notice
Draft

Not for implementation. Contains non-binding recommendations.

Docket Number:
FDA-2019-D-1536
Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research

The purpose of this guidance is to describe the benefit-risk assessment framework that the 17 Agency uses in evaluating whether applications for opioid analgesic drugs meet the standard for 18 approval under section 505 of the Federal Food, Drug, and Cosmetic Act. This guidance 19 summarizes the information that should be included in a new drug application for an opioid 20 analgesic drug to facilitate the Agency’s benefit-risk assessment.

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2019-D-1536.

 
Back to Top